CoChat

Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy

Open access
Kurita, Yusuke, Araya, Jun, Minagawa, Shunsuke, Hara, Hiromichi, Ichikawa, Akihiro, Saito, Nayuta, Kadota, Tsukasa, Tsubouchi, Kazuya, Sato, Nahoko, Yoshida, Masahiro, Kobayashi, Kenji, Ito, Saburo, Fujita, Yu, Utsumi, Hirofumi, Yanagisawa, Haruhiko, Hashimoto, Mitsuo, Wakui, Hiroshi, Yoshii, Yutaka, Ishikawa, Takeo, Numata, Takanori, Kaneko, Yumi, Asano, Hisatoshi, Yamashita, Makoto, Odaka, Makoto, Morikawa, Toshiaki, Nakayama, Katsutoshi, Kuwano, Kazuyoshi · 2017 · Respiratory Research
Cited by 98

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Pirfenidone (PFD) is an anti-fibrotic agent used to treat idiopathic pulmonary fibrosis (IPF), but its precise mechanism of action remains elusive. Accumulation of profibrotic myofibroblasts is a crucial process for fibrotic remodeling in IPF. Recent findings show participation of autophagy/mitophagy, part of the lysosomal degradation machinery, in IPF pathogenesis. Mitophagy has been implicated in myofibroblast differentiation through regulating mitochondrial reactive oxygen species (ROS)-mediated platelet-derived growth factor receptor (PDGFR) activation. In this study, the effect of PFD on autophagy/mitophagy activation in lung fibroblasts (LF) was evaluated, specifically the anti-fibrotic property of PFD for modulation of myofibroblast differentiation during insufficient mitophagy. METHODS: Transforming growth factor-β (TGF-β)-induced or ATG5, ATG7, and PARK2 knockdown-mediated myofibroblast differentiation in LF were used for in vitro models. The anti-fibrotic role of PFD was examined in a bleomycin (BLM)-induced lung fibrosis model using PARK2 knockout (KO) mice. RESULTS: We found that PFD induced autophagy/mitophagy activation via enhanced PARK2 expression, which was partly involved in the inhibition of myofibroblast differentiation in the presence of TGF-β. PFD inhibited the myofibroblast differentiation induced by PARK2 knockdown by reducing mitochondrial ROS and PDGFR-PI3K-Akt activation. BLM-treated PARK2 KO mice demonstrated augmentation of lung fibrosis and oxidative modifications compared to those of BLM-treated wild type mice, which were efficiently attenuated by PFD. CONCLUSIONS: These results suggest that PFD induces PARK2-mediated mitophagy and also inhibits lung fibrosis development in the setting of insufficient mitophagy, which may at least partly explain the anti-fibrotic mechanisms of PFD for IPF treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12931-017-0600-3

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 98

Metadata

Authors
Kurita, Y., Araya, J., Minagawa, S., Hara, H., Ichikawa, A., Saito, N., Kadota, T., Tsubouchi, K., Sato, N., Yoshida, M., Kobayashi, K., Ito, S., Fujita, Y., Utsumi, H., Yanagisawa, H., Hashimoto, M., Wakui, H., Yoshii, Y., Ishikawa, T., Numata, T., Kaneko, Y., Asano, H., Yamashita, M., Odaka, M., Morikawa, T., Nakayama, K., & Kuwano, K.
Venue
Respiratory Research
Published
2017-06-02
Volume
18
Issue
1
Pages
114-114
ISSN
  • 1465-9921 (ISSN-L)
  • 1465-993X
OpenAlex
W2621087035
Cited by
98
References
8
FWCI
7.90
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy. https://app.cochat.ai/papers/10.1186/s12931-017-0600-3
The paper
Kurita, Y., Araya, J., Minagawa, S., Hara, H., Ichikawa, A., Saito, N., Kadota, T., Tsubouchi, K., Sato, N., Yoshida, M., Kobayashi, K., Ito, S., Fujita, Y., Utsumi, H., Yanagisawa, H., Hashimoto, M., Wakui, H., Yoshii, Y., Ishikawa, T., . . . Kuwano, K. (2017). Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy. Respiratory Research. https://doi.org/10.1186/s12931-017-0600-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.